High-dose allopurinol modulation of 5-FU toxicity: phase I trial of an outpatient dose schedule.
Cancer Treat Rep
; 66(9): 1723-7, 1982 Sep.
Article
em En
| MEDLINE
| ID: mdl-7116349
ABSTRACT
In an attempt to decrease the activation of 5-FU by normal cells relative to cancer cells, 20 patients with metastatic cancer were given 72 courses of 5-FU and allopurinol (HPP) in a phase I trial. 5-FU was given daily by iv bolus injection for 5 consecutive days every 4 weeks HPP, 300 mg orally every 8 hours for 6 consecutive days, was started 24 hours before the first injection of 5-FU. HPP appeared to modulate 5-FU toxicity by allowing higher doses (18-21 mg/kg daily for 5 days) to be given. Unexpectedly, neurotoxicity was the dose-limiting toxicity; it was slowly reversible and manifested primarily as encephalopathy, with some patients having cerebellar signs. Gastrointestinal and hematologic toxic effects were mild and infrequent. Because of the high incidence of neurotoxicity and low response rate, this program does not appear to offer any advantages over conventional dose schedules of 5-FU alone.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Adenocarcinoma
/
Alopurinol
/
Fluoruracila
Limite:
Aged
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Cancer Treat Rep
Ano de publicação:
1982
Tipo de documento:
Article